Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

NASDAQ AEZS opened at $2.75 on Monday. The company’s 50-day simple moving average is $2.94 and its two-hundred day simple moving average is $3.93. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The company has a market capitalization of $4.92 million, a price-to-earnings ratio of -0.18 and a beta of 1.55.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.